Immunogenicity of virus-like particle vaccine candidates against SARS-CoV-2 infection.

Access microbiology Pub Date : 2025-02-17 eCollection Date: 2025-01-01 DOI:10.1099/acmi.0.000925.v3

Hai Trong Nguyen, Ravendra Garg, Andrea Kroeker, Volker Gerdts, Darryl Falzarano, Qiang Liu

{"title":"Immunogenicity of virus-like particle vaccine candidates against SARS-CoV-2 infection.","authors":"Hai Trong Nguyen, Ravendra Garg, Andrea Kroeker, Volker Gerdts, Darryl Falzarano, Qiang Liu","doi":"10.1099/acmi.0.000925.v3","DOIUrl":null,"url":null,"abstract":"<p><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve, potentially leading to variants of concern that could become more transmissible, resist treatment, evade host immunity and reduce the effectiveness of currently available vaccines. Improved vaccines are still required as vaccination remains the most effective strategy against this virus. We have produced two SARS-CoV-2 virus-like particles (VLPs) using a baculovirus BacMam expression platform and examined their immunogenicity in mice. VLP1 contains the spike protein from the Wuhan strain, whereas VLP2 contains that of an Omicron variant. Mice immunized with VLP1 and boosted with VLP2 developed significantly higher antibodies in the sera, as well as higher numbers of IFN-γ secreting cells than the control group. Furthermore, both VLPs induced virus-neutralizing antibodies against Wuhan and Omicron variants. In conclusion, VLPs have the potential for the development of a safe and effective vaccine against SARS-CoV-2 variants.</p>","PeriodicalId":94366,"journal":{"name":"Access microbiology","volume":"7 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833050/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Access microbiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1099/acmi.0.000925.v3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve, potentially leading to variants of concern that could become more transmissible, resist treatment, evade host immunity and reduce the effectiveness of currently available vaccines. Improved vaccines are still required as vaccination remains the most effective strategy against this virus. We have produced two SARS-CoV-2 virus-like particles (VLPs) using a baculovirus BacMam expression platform and examined their immunogenicity in mice. VLP1 contains the spike protein from the Wuhan strain, whereas VLP2 contains that of an Omicron variant. Mice immunized with VLP1 and boosted with VLP2 developed significantly higher antibodies in the sera, as well as higher numbers of IFN-γ secreting cells than the control group. Furthermore, both VLPs induced virus-neutralizing antibodies against Wuhan and Omicron variants. In conclusion, VLPs have the potential for the development of a safe and effective vaccine against SARS-CoV-2 variants.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Access microbiology

CiteScore

2.00

自引率

0.00%

发文量